tbuckley/cabot-search huggingface dataset:
Effect of the Healthy Hunger-Free Kids Act on the Nutritional Quality of Meals Selected by Students and School Lunch Participation Rates
Authors: Donna B. Johnson, Mary Podrabsky, Anita Rocha, Jennifer J. Otten
Journal: JAMA Pediatrics (2016)

<h3>Importance</h3> Effective policies have potential to improve diet and reduce obesity. School food policies reach most children in the United States. <h3>Objective</h3> To assess the nutritional quality of foods chosen by students and meal participation rates before and after the implementation of new school meal standards authorized through the Healthy Hunger-Free Kids Act. <h3>Design, Setting, and Participants</h3> This descriptive, longitudinal study examined changes in the nutritional quality of 1 741 630 school meals at 3 middle schools and 3 high schools in an urban school district in Washington state. Seventy two hundred students are enrolled in the district; 54% are eligible for free and reduced-price meals. Student food selection data were collected daily from January 2011 through January 2014 during the 16 months prior to and the 15 months after implementation of the Healthy Hunger-Free Kids Act. <h3>Exposure</h3> The Healthy Hunger-Free Kids Act. <h3>Main Outcomes and Measures</h3> Nutritional quality was assessed by calculating monthly mean adequacy ratio and energy density of the foods selected by students each day. Six nutrients were included in the mean adequacy ratio calculations: calcium, vitamin C, vitamin A, iron, fiber, and protein. Monthly school meal participation was calculated as the mean number of daily meals served divided by student enrollment. Mean monthly values of mean adequacy ratio, energy density, and participation were compared before and after policy implementation. <h3>Results</h3> After implementation of the Healthy Hunger-Free Kids Act, change was associated with significant improvement in the nutritional quality of foods chosen by students, as measured by increased mean adequacy ratio from a mean of 58.7 (range, 49.6-63.1) prior to policy implementation to 75.6 (range, 68.7-81.8) after policy implementation and decreased energy density from a mean of 1.65 (range, 1.53-1.82) to 1.44 (range, 1.29-1.61), respectively. There was negligible difference in student meal participation following implementation of the new meal standards with 47% meal participation (range, 40.4%-49.5%) meal participation prior to the implemented policy and 46% participation (range, 39.1%-48.2%) afterward. <h3>Conclusions and Relevance</h3> Food policy in the form of improved nutrition standards was associated with the selection of foods that are higher in nutrients that are of importance in adolescence and lower in energy density. Implementation of the new meal standards was not associated with a negative effect on student meal participation. In this district, meal standards effectively changed the quality of foods selected by children.
Pain in scar as an early symptom of acquired thoracic lung hernia
Authors: JC Meek, E Bollen, J Koudstaal, C Versteege, FP Maesen
Journal: European Respiratory Journal (1991)

Hernia of the lung manifests itself as an elastic, usually replaceable, swelling in the chest wall, which changes in size during inspiration and expiration. It does not generally cause any symptoms. We describe the case history of a 49 yr old man with an acquired thoracic lung hernia, which had first presented three years previously as pain in an operation scar during coughing and lifting. Histopathology of the excised lung tissue showed abnormalities suggestive of previous episodes of strangulation.
A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects
Authors: F. Piaggio, V. Kondylis, F. Pastorino, D. Di Paolo, P. Perri, I. Cossu, F. Schorn, C. Marinaccio, D. Murgia, A. Daga, F. Raggi, M. Loi, L. Emionite, E. Ognio, M. Pasparakis, D. Ribatti, M. Ponzoni, C. Brignole
Journal: Journal of Controlled Release (2015)
A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.
Authors: T Philip, R Ghalie, R Pinkerton, J M Zucker, J L Bernard, G Leverger, O Hartmann
Journal: Journal of Clinical Oncology (1987)

Forty-seven children or adolescents with initial stage IV (42 patients) or stage III (five) advanced neuroblastoma (12 were progressing after relapse and 35 had never reached complete remission [CR] after conventional therapy) were included in a phase II study of the combination of high-dose VP-16 (100 mg/m2/d X 5) and high-dose cisplatin (CDDP) (40 mg/m2/d X 5). Twenty patients had received prior CDDP therapy (total dose, 100 to 640 mg/m2; median, 320 mg/m2) and 38 of 47 had bone marrow involvement when included in the study. The overall response rate was 55%, with 22% CR. Duration of response was 5 to 18 months, with a median of 10 months. Eight patients are still disease free, with a median observation time of 13 months, but all had received additional therapy after two courses of this regimen. Gastrointestinal toxicity was frequent but tolerable. Myelosuppression was severe but of brief duration, ie, nadir of neutrophils was observed at day 15 with 95% of the patients recovering a normal count before day 28, and nadir of platelet count was at day 17 with only two severe and reversible episodes of bleeding. The overall incidence of sepsis was 8% (seven of 92 courses), with no death related to infection. No acute renal failure was observed after two courses, and only three of 47 children experienced a clear reduction of renal function. After two courses, only two children showed a hearing loss in the 1,000 to 2,000 Hz range, although hearing loss above the 2,000 Hz level was frequently encountered. It is concluded that high-dose VP-16 and CDDP is an effective regimen in advanced neuroblastoma with acceptable toxicity. Phase III studies are needed in previously untreated patients. J Clin Oncol 5:941-950.
Sphincter Preservation for Rectal Cancer: Fact or Fiction?
Authors: Bruce D. Minsky
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.8.1971 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11956254 Sphincter Preservation for Rectal Cancer: Fact or Fiction? Bruce D. MinskyxBruce D. MinskySearch for articles by this author Show More Memorial Sloan-Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.2002.20.8.1971 Full Text PDF Figures and Tables "Sphincter Preservation for Rectal Cancer: Fact or Fiction?." Journal of Clinical Oncology, 20(8), pp. 1971–1972© 2002 by American Society of Clinical Oncology
Addressing Distress in Patients With Head and Neck Cancers: A Mental Health Quality Improvement Project
Authors: Natalie Riblet, Karen Skalla, Auden McClure, Karen Homa, Alison Luciano, Thomas H. Davis
Journal: Journal of the National Comprehensive Cancer Network (2014)

This study sought to improve mental health care for patients with head and neck cancers (HNCs) through the implementation of an evidence-based process for identifying and managing psychological distress. This process in an HNC medical oncology clinic was assessed and redesigned using quality improvement (QI) methods from November 2010 through April 2012. The redesign, starting in January 2011, involved a 2-component QI intervention: the validated NCCN Distress Thermometer and an evidence-based treatment decision algorithm. Screening processes were improved through Plan-Do-Study-Act (PDSA) cycles. Before January 2011, distress identification was based on a provider's clinical assessment. Cause-effect diagramming suggested that lack of a formalized process for distress assessment contributed to missed diagnoses. Providers were also unfamiliar with mental health resources. After implementing process changes, biweekly distress screening rates rose from 0% to 38% between January and July 2011. Furthermore, with additional PDSA cycles, these rates increased to 74% between October 2011 and April 2012. Similar to proposed benchmarks, 84% (n=47) of newly diagnosed patients (n=56) were screened. Improvement in screening was attributed to process changes and involvement of senior leadership. QI principles can be applied to the cancer setting in order to create systems of care which more reliably identify and address the needs of patients with psychological distress.
Abstract 17179: Uremic Toxins Contribute to Cardiac Fibrosis after Myocardial Infarction: Role of MicroRNAs
Authors: Indrajeet Rana, Andrew Kompa, Joanna Skommer, Suree Lekawanvijit, Darren J Kelly, Henry Krum, Fadi J Charchar
Journal: Circulation (2014)

Introduction: A decline in renal function is a common consequence of myocardial infarction (MI) resulting in increased cardiovascular events, known as cardiorenal syndrome (CRS). Although molecular mechanisms contributing to CRS are not well understood, a role for elevated plasma levels of the uremic toxin indoxyl sulphate (IS) and increased fibrosis have been described. MicroRNAs are small endogenously transcribed regulatory RNAs that modulate gene expression and regulate many cardiac processes involved in cardiac dysfunction. Aim: Using a rat model we investigated whether MI leads to changes in expression of cardiac microRNA-21 and microRNA-29, both known to contribute to fibrosis. We also investigated the effect of lowering plasma uremic toxins on cardiac expression of these microRNAs. Methods: MI was induced by coronary artery ligation in male Sprague-Dawley rats. At 16 weeks cardiac function was measured prior to sacrifice. Cardiac tissues were assessed for molecular changes using real-time PCR, western blot analysis and histological methods. Results: MI significantly increased cardiac microRNA-21, collagen1A1, fibronectin-1 and TGFβ1 mRNA expression, as well as cardiac fibrosis and collagen 1 protein expression. Conversely, microRNA-29 expression was reduced in the heart (Table). Treatment with the AST-120 significantly reversed all these changes (Table). MicroRNA-21 levels significantly correlated with mRNA for TGF-β1 (P=0.049; r2=0.17) and its target genes collagen1A1 (P=0.004; r2=0.35) and fibronectin-1 (P=0.003; r2=0.52). MicroRNA-29b levels negatively and significantly correlated with TGF-β1 (P=0.017; r2=0.26) and collagen1A1 (P=0.048; r2=0.18) and fibronectin-1 (P=0.013; r2=0.29). Conclusions: We report a link between the beneficial effects of lowering circulating uremic toxins and microRNAs changes in the heart. Targeting microRNA’s may provide a therapeutic target for the treatment of CRS.
Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Victoria Panagiota, Michael Heuser, Michelle Maria Araujo Cruz, Anita Badbaran, Rabia Shahswar, Ioanna N Triviai, Boris Fehse, Haefaa Alchalby, Ulrich Lehmann, Christian Koenecke, Anuhar Chaturvedi, Michael Stadler, Matthias Eder, Gudrun Göhring, Michael Koenigsmann, Brigitte Schlegelberger, Hans Heinrich Kreipe, Arnold Ganser, Felicitas Thol, Nicolaus Kröger
Journal: Blood (2014)
Recommendations of the ESGE Workshop on Ethical, Clinical, and Economic Dilemmas Arising from the Implementation of New Techniques
Authors: J. Devière, J. Hochberger, H. Neuhaus, T. Ponchon, N. Eugenidis, C. Neumann, S. Ladas
Journal: Endoscopy (2003)

In this workshop, certain diagnostic and interventional endoscopic procedures were discussed regarding their current status, risks involved, ethical concerns, and recommendations.
Reply
Authors: Miki Yokokawa, Hyungjin Myra Kim, Kazim Baser, William Stevenson, Koichi Nagashima, Paolo Della Bella, Pasquale Vergara, Gerhard Hindricks, Arash Arya, Katja Zeppenfeld, Marta de Riva Silva, Emile G. Daoud, Sunil Kumar, Karl-Heinz Kuck, Roland Tilz, Shibu Mathew, Hamid Ghanbari, Rakesh Latchamsetty, Fred Morady, Frank Bogun
Journal: Journal of the American College of Cardiology (2015)
LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study
Authors: G.R. Foster, S. Pianko, C. Cooper, A. Brown, D. Forton, R.G. Nahass, J. George, E. Barnes, D.M. Brainard, B. Massetto, M. Lin, J.G. McHutchison, G.M. Subramanian, K. Agarwal
Journal: Journal of Hepatology (2015)
Community programme boasts initial success
Authors: A. Nesbitt, M. Jackson
Journal: BMJ (1995)

0Io io io 40 O 10 20 30 40 5o Week Weekly measles notifications in 1987-8 (when last measles epidemic occurred) and 1994, England and Wales their stage of development, to break chains of transmission.When the campaign was planned different methods of delivering services were costed.The cost of preventing an epidemic was estimated at around C20m for the vaccine,
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
Authors: J Laubach, L Garderet, A Mahindra, G Gahrton, J Caers, O Sezer, P Voorhees, X Leleu, H E Johnsen, M Streetly, A Jurczyszyn, H Ludwig, U-H Mellqvist, W-J Chng, L Pilarski, H Einsele, J Hou, I Turesson, E Zamagni, C S Chim, A Mazumder, J Westin, J Lu, T Reiman, S Kristinsson, D Joshua, M Roussel, P O'Gorman, E Terpos, P McCarthy, M Dimopoulos, P Moreau, R Z Orlowski, J S Miguel, K C Anderson, A Palumbo, S Kumar, V Rajkumar, B Durie, P G Richardson
Journal: Leukemia (2015)
Meta-analysis finds no evidence for efficacy of nalmefene in treating alcohol dependence
Authors: Susan Mayor
Journal: BMJ (2015)

Current evidence from randomised controlled trials does not support the use of the opioid antagonist nalmefene for treating alcohol dependence, shows a systematic review that the authors said questioned decisions by some regulatory authorities to approve the drug for this indication.

The review, published in PLoS Medicine , analysed all available randomised controlled trials evaluating nalmefene to treat alcohol dependence in adults.1 The researchers included five trials that met their inclusion criteria to compare the opioid antagonist with placebo, in 2567 adults with alcohol dependence.

Their results …
Management for Doctors: Using information for managing clinical services effectively
Authors: T. Scott, P. Jackson
Journal: BMJ (1995)

The first report of the Audit Commission suggested that cases suitable for day surgery were being treated inefficiently.1 Huddersfield featured well below the median for the percentage of those procedures that were performed as day cases. This prompted a local review.

One of the procedures was dilatation and curettage. The Audit Commission suggested that 86% of these procedures should be performed as day cases despite the fact that fewer than 50% of these were being performed as day cases in half the districts surveyed. Huddersfield was stated to have a rate of 32%. The gynaecological clinical audit group carried out an initial review using information from the computerised clinical information system of all dilatation and curettage procedures performed during the previous two years. The audit meetings are attended by all medical staff working in the department and are open to nurses, nurse managers, and medical students. They are chaired by a consultant who is also the gynaecological representative on the clinical directorate.

A total of 966 cases of dilatation and curettage had been carried out in the two years. The survey revealed that 23.5% of the patients were under the age of 35 years (fig 1). The most common presenting symptom was excessive or frequent menstrual losses (38% of all cases), with irregular bleeding, intermenstrual bleeding, and infertility being other less common symptoms. None of the patients under the age of 50 had malignant disease. Even in patients presenting with postmenopausal bleeding only 12.1% had either malignant disease (adenomatous or squamous carcinoma) or potentially premalignant changes (atypical endometrial hyperplasia) (fig 2).



fig 1 
Ages of patients who had dilatation and curettage. Values are percentages





fig 2 
Findings on dilatation and curettage. Values are percentages



The clinicians agreed that a dilatation and curettage was essentially a diagnostic test and that its most vital …
Amoxicillin for clinically unsuspected pneumonia in primary care: subgroup analysis
Authors: Jolien Teepe, Paul Little, Nori Elshof, Berna D.L. Broekhuizen, Michael Moore, Beth Stuart, Chris C. Butler, Kerenza Hood, Margareta Ieven, Samuel Coenen, Herman Goossens, Theo J.M. Verheij
Journal: European Respiratory Journal (2015)

Antibiotic treatment is recommended for pneumonia [1, 2]. However, some studies have suggested that the milder spectrum of pneumonia in primary care does not have important adverse consequences if missed and, therefore, managed without antibiotics [3–5]. Better insight in the effects of antibiotics for pneumonia in primary care could improve patient information and management.
Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers
Authors: L. H. Camacho, D. S. Hong, C. Gutierrez, S. Vertovsek, N. Tannir, C. A. Parker, M. A. Purdom, J. Lewis, R. P. Gale, R. Kurzrock
Journal: Journal of Clinical Oncology (2006)

13041 Background: Arsenics are potent anti-cancer drugs. Organic arsenics are much less toxic than inorganic arsenics (like arsenic trioxide [As 2 O 3 ]). We synthesized ZIO-101 (S-dimethylarsino-glutathione) by conjugating dimethylarsenic to glutathione. ZIO-101 is active against multiple cancers in in vitro tests and animals. In mice, the LD 50 of ZIO-101 is about 50-fold higher than As 2 O 3. At equimolar extracellular arsenic concentrations of ZIO-101 and As 2 O 3 , intracellular arsenic concentrations are about 15-fold higher with ZIO-101 than As 2 O 3 . In cancer cells this results in dramatically more mitochondrial damage and more apoptosis induction. Preclinical data suggest ZIO-101 may induce apoptosis by different mechanisms than As 2 O 3 and can kill As 2 O 3 -resistant cancer cells. Methods: A phase-1 study evaluating the safety and pharmacokinetic profile of ZIO-101 in pts with advanced cancers. 18 patients enrolled in 5 cohorts. Mean Age 63 (42–79). Starting dose was 78 mg/m 2 /d IV for 5 days every month with 40% dose increases. Results: Thirty-three courses of ZIO-101 have been delivered. Therapy with ZIO-101 was safe. Toxicities ≥ grade-2 include Fatigue (N = 4), Vomiting (N = 4), and Anorexia (N = 2). One patient with rapidly progressing metastatic renal cell cancer had complete resolution of a brain metastasis and stable disease elsewhere (beyond 6 months). Pharmacokinetic (PK) studies at 214 mg/m 2 /d showed a t max = 1 h (no SD), C max = 685 μg/mL (SD ± 130 μg/mL), t 1/2 = 13.9 h (SD ± 0.3 h) and AUC 0-∞ = 14.9 μg.h/mL (SD ± 2.6μg.h/mL). Conclusions: Clinical and PK data show ZIO-101 is safe at doses that result in blood levels that have substantial anti-cancer activity at in vivo concentrations. There is early evidence of clinical activity. Dose-escalation continues. Results on subsequent dose-levels will be presented. [Table: see text]
Online Therapy Reduces Suicide Ideation in Medical Interns
Authors: Anita Slomski
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ivanka Zdenka Matylda Anna Richarda Myskova
Authors: Roslyn Jamieson
Journal: BMJ (2015)

Ivanka Zdenka Matylda Anna Richarda Myskova (nee Schneider, known as “Iva”) was an inspirational woman born in Nectiny in the Sudetenland; her family were of Czech origin.

She and her brother were the sixth generation of her family to practise medicine. Earlier generations were physicians to the von Furstenberg family, and Iva’s father, Richard Schneider, became GP to the German community of Nectiny.

Iva’s early life was disrupted by warfare and politics. Hitler was already engaging in the “purification and perfecting” of the German people by exterminating those he deemed as imperfect, when appeasement resulted in the ceding of the Sudetenland to him. The Schneider family were expelled from Nectiny and escaped to Plasy, a village near Pilsen, Czechoslovakia. They lived there in an apartment in a Cistercian monastery adjoining the Metternich Princes’ Chateau. As the second world war broke out, her parents became involved with the local resistance movement. Iva started her schooling, and her father continued to practise as a doctor. …
An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
Authors: Tarsem Mougdil, Christopher Paustian, Zipei Feng, Rom Leidner, Christopher Dubay, Brendan D Curti, Hong-Ming Hu, Walter Urba, Carlo Bifulco, Bernard Fox, Brian Bell
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Head and neck squamous cell carcinoma (HNSCC) is the 6th leading cause of cancer by incidence worldwide with approximately 600,000 new cases per year. While some patients respond to immunotherapy, the majority of patients fail to experience benefit. Our group formed a
Levobunolol
Authors: Frank G. Berson, David L. Epstein, Leon G. Partamian, Alfonse Cinotti, Howard Cohen, Peter Fries, Robert David, Ben Gurion, Efraim Duzman, Gary D. Novack, John L. Lue, Robert J. Foerster, Miles Galin, Jonathan Lass, Manuel Ober, Armin Scharrer, Dong Shin, David E. Silverstone
Journal: Ophthalmology (1985)
The Case for Tailored Prostate Cancer Screening: An NCCN Perspective
Authors: Michelle L. McDonald, J. Kellogg Parsons
Journal: Journal of the National Comprehensive Cancer Network (2015)

A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate-cancer mortality yet limit overdetection of clinically insignificant disease. Use of newer biomarkers that increase specificity for prostate cancer detection, including percentage of free PSA, 4Kscore, prostate health index, prostate cancer antigen 3, and multiparametric MRI may be considered under certain circumstances.
Diagnostic Accuracy of Stress Perfusion CMR in Comparison With Quantitative Coronary Angiography
Authors: Federico E. Mordini, Tariq Haddad, Li-Yueh Hsu, Peter Kellman, Tracy B. Lowrey, Anthony H. Aletras, W. Patricia Bandettini, Andrew E. Arai
Journal: JACC. Cardiovascular imaging (2014)